APUS vs SLRX vs NUVB vs CRL

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Apimeds Pharmaceuticals US, Inc (APUS) delivered a total return of -33.

2%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: CRL returned +119. 2% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Apimeds Pharmaceuticals US, Inc (APUS) is the lower-risk stock at 0.

82β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 148% more volatile than APUS relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Apimeds Pharmaceuticals US, Inc (APUS) is the more profitable company, earning 0.

0% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 157.

3% to $12. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Apimeds Pharmaceuticals US, Inc (APUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82)). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (APUS: -33. 2%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: APUS is a small-cap quality compounder stock; SLRX is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.